IVIGmycophenolate mofetilsystemic sclerosisLos Angeles grade A esophagitisLos Angeles grade B esophagitisSSc
…rature review (2024) suggests that intravenous immunoglobulins (IVIG) may offer significant therapeutic benefit in gastrointestinal …
100articles mentioning drugs
120drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Mycophenolate mofetil ×
Mycophenolate mofetil
This drug is selected. Its supporting articles are shown below.
Articles mentioning Mycophenolate mofetil
100 articles · page 3 of 9bosentanmethotrexatemycophenolate mofetilMTXMMFsystemic sclerosis (SSc)digital ulcersImmunosuppressive therapyDigital ulcers (DUs)
…development of a new digital ulcer despite at least 24 weeks of bosentan therapy. We included patients who were receiving concurrent tre…
IloprostSildenafilalprostadilBosentantadalafilMycophenolate mofetilnifedipineciprofloxacinflucloxacillinNintedanib+5 more
…ostadil in 2013 and iloprost in 2016, both initially effective. Iloprost was successfully re-administered in 2019 and 2024 but discontin…
Mycophenolate MofetilMMFiloprostPDE5iMMF-treatedERAsystemic sclerosis (SSc)interstitial lung diseaseinterstitial lung disease (ILD)cutaneous fibrosis+1 more
…Introduction The prescription of Mycophenolate Mofetil (MMF) represents the primary treatment for interstitial lung di…
hydroxychloroquinecolchicineMethotrexatemycophenolate mofetiltocilizumabUpadacitinibabataceptcyclosporineprednisonemethylprednisolone+3 more
…ed so was discontinued.Other medications tried were colchicine, hydroxychloroquine, IV-Ig, and cyclosporine, tocilizumab and abatacept with subopt…
P.211 Ruxolitinib therapy in pansclerotic morphea refractory to autologous stem-cell transplantation
ruxolitinibMycophenolate mofetilcyclophosphamiderituximababatacepttocilizumabmethotrexatePansclerotic morphea (PSM)
… kinase (JAK) – STAT signalling in PSM pathogenesis, suggesting ruxolitinib, a JAK 1/2 inhibitor, as potential therapeutic option [N Engl J…
mycophenolate mofetilhydroxychloroquinemethotrexatelcSScinterstitial lung diseasediffuse cutaneous systemic sclerosismyositisCanadian Scleroderma Research Groupmyocarditisarthritis
…ial lung disease (68%). The top first-line drugs of choice were mycophenolate mofetil (47%), methotrexate (28%) and hydroxychloroquine (20%).Conclusi…
prednisolonecyclophosphamidemycophenolate mofetilrituximabRTXsystemic sclerosis (SSc)immunosuppressive therapySSc
…. The mean disease duration was 7.4±6.4 years. All pts received prednisolone at mean dose of 10±4 mg/day. 11% of patients received cyclophos…
prednisonemycophenolate mofetilmethotrexatetocilizumabrituximabCalcinosis cutiscalcinosis cutisAbstractsystemic sclerosisSSccakinosis cutis+1 more
…tremities (71% knees), and 1 facial lesion. Treatments included prednisone (76%), mycophenolate mofetil (64%), endothelin receptor antagon…
mycophenolate mofetilrituximabcyclophosphamideSystemic sclerosis
… exchange (TPE), cyclophosphamide, and maintenance therapy with mycophenolate mofetil or rituximab in cases of intolerance. Samples were obtained at …
mycophenolatecyclophosphamidemycophenolate mofetilidiopathic pulmonary fibrosisSSc-ILDsystemic sclerosis-associated interstitial lung disease (SSc-ILD)
… baseline HRCT predicted PPF in patients with SSc-ILD receiving mycophenolate or cyclophosphamide therapy. Future independent prospective coh…
mycophenolate mofetilmethotrexatecyclophosphamiderituximabfludarabineanti-thymocyte globulinDiffuse cutaneous systemic sclerosis (dcSSc)dcSSc
… AHSCT after failing standard therapies including methotrexate, mycophenolate mofetil, cyclophosphamide, and rituximab. The conditioning regimen cons…